Clinical Trials
111 trialsTAPUR
American Society of Clinical Oncology
THREAD
University of Utah
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
St. Justine's Hospital
MegaMOST
Centre Leon Berard
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Massachusetts General Hospital
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
City of Hope Medical Center
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Massachusetts General Hospital
Match Mel
Melanoma Institute Australia
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute
DETERMINE
Cancer Research UK
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
M.D. Anderson Cancer Center
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Kentucky
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
M.D. Anderson Cancer Center
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
M.D. Anderson Cancer Center
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Neo Combi
Melanoma Institute Australia
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
HEM-iSMART D
Princess Maxima Center for Pediatric Oncology
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Jonsson Comprehensive Cancer Center
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Fudan University
PLGG - MEKTRIC
University Hospital, Strasbourg, France
M14LTK
The Netherlands Cancer Institute
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Fujian Medical University
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
University of Miami
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Ann & Robert H Lurie Children's Hospital of Chicago
Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
University of California, Davis
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Imatinib and Trametinib for KRAS-mutated Solid Tumor
China Medical University Hospital
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
MATRIX-Rare
Oslo University Hospital
NETCAM-RCT
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
Memorial Sloan Kettering Cancer Center
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Haukeland University Hospital
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
CombiRT
Melanoma and Skin Cancer Trials Limited
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
NETCAM
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
ALTREM
Assistance Publique Hopitaux De Marseille
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
FINPROVE
Helsinki University Central Hospital